VICTORIA, Jan. 6, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES
LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF)
announced today IPA will be in San Francisco during the
J.P. Morgan 38th Annual Healthcare Conference events running
from January 13-16, 2020 in San Francisco,
California. The annual J.P. Morgan
Healthcare Conference is the largest and most informative
healthcare investment symposium in the industry, bringing together
industry leaders, emerging fast-growth companies, innovative
technology creators, and members of the investment community.
Thirty-eight years ago, this meeting launched as a boutique
event with only 20 companies focused on biotechnology. Now it
attracts more than 450 companies, both public and private, to
deliver presentations to more than 9,000 attendees. Global thought
leaders and biotech industry experts share their ideas and
strategies with investors to reshape the industry.
Jennifer Bath, ImmunoPrecise
President and CEO, Frederic Chabot,
Investor Relations, and Brian
Lundstrum, Director, will be taking investor and business
development meetings throughout the conference. To request a
meeting please email Sue LeGare.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is an international, full-service, therapeutic
antibody discovery company offering species agnostic advancements
such as the B cell Select™ progressive, single-cell interrogation
technology and the DeepDisplay™ custom phage libraries, as well as
the Abthena™ bispecific program. IPA is focused on the next
generation of antibody discovery, to deliver the most
therapeutically relevant antibodies, in a shorter timeframe, with
the highest probability of succeeding to clinical trials.
ImmunoPrecise's discovery and development are conducted in
Utrecht and Oss, the Netherlands (U-Protein Express and IPA
Europe, respectively), and in Victoria,
British Columbia (IPA Canada). The Company operates globally
to offer a continuum of superior antibody services, transforming
the face of therapeutic discovery, by decreasing turnaround time
and risk, and promoting clinical success.
Forward Looking Information
This news release contains statements that, to the extent
they are not recitations of historical facts, may constitute
"forward-looking statements" within the meaning of applicable
Canadian securities laws. The Company uses words such as "may",
"would", "could", "will", "likely", "expect", "believe", "intend"
and similar expressions to identify forward-looking statements. Any
such forward-looking statements are based on assumptions and
analyses made by ImmunoPrecise in light of its experience and its
perception of historical trends, current conditions and expected
future developments. However, whether actual results and
developments will conform to ImmunoPrecise's expectations and
predictions is subject to any number of risks, assumptions and
uncertainties. Many factors could cause ImmunoPrecise's actual
results to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Such
factors include, among other things, actual revenues and earnings
for ImmunoPrecise being lower than anticipated, and those risks and
uncertainties described in ImmunoPrecise's annual management
discussion and analysis for the fiscal period ended October 31, 2019 which can be accessed at
www.sedar.com. The "forward-looking statements" contained
herein speak only as of the date of this press release and, unless
required by applicable law, ImmunoPrecise undertakes no obligation
to publicly update or revise such information, whether as a result
of new information, future events or otherwise.
SOURCE ImmunoPrecise Antibodies Ltd.